Abstract: A method of reducing elevated intraocular pressure which comprises administering the compound of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof to patients suffering from abnormally elevated intraocular pressure is provided. A pharmaceutical formulation containing the compound of the formula (1) as an essential component is also provided.

Abstract: A method for detecting the presence of a specific analyte in solution comprising the steps of affixing to a chromatographic medium a first antibody which binds with specificity to the analyte in a pattern which forms a pre-determined geometric symbol or symbols consisting of a plurality of line segments; partially blocking or obstructing the expected passage of a moving phase or solvent through the symbol; reacting the solution to a marker-second antibody complex which binds with specificity to the analyte to form analyte-marker-second antibody complexes in the presence of the analyte; eluting the solution containing any analyte-marker-second antibody complex through the partially blocked or obstructed medium; and observing the substantially complete formation, or lack thereof, of the predetermined geometric symbol or symbols by means of the marker.

Abstract: A pharmaceutical formulation in the form of aqueous suspension which comprises an ion exchange resin carrying an active ingredient and a suspending agent, characterized in that the formulation further contains a basic or neutral amino acid or a salt thereof as a dispersion stabilizer.

Abstract: A method of reducing elevated intraocular pressure which comprises administering the compound of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof to patients suffering from abnormally elevated intraocular pressure is provided. A pharmaceutical formulation containing the compound of the formula (1) as an essential component is also provided.

Abstract: An immunochromatography which comprises chromatographically moving a sample together with or followed by labelling fine particles in a chromatographic medium having at least one reaction site having immobilized thereat a reagent bindable to a substance to be detected in a sample, to contact the above sample and the labelling fine particles with the above reaction site, and detecting the substance to be detected by use of the phenomenon that when the above substance to be detected is present in the sample the labelling fine particles are specifically bound to the above immobilized reagent via the substance to be detected at the above reaction site, to thereby capture the substance to be detected on the chromatographic medium, characterized in that the above labelling fine particles are sensitized dyed particles obtained by sensitizing, with a material bindable to the above substance to be detected, labelling dyed particles obtained by dyeing latex particles of a synthetic high polymer, said labelling dyed part

Abstract: A pharmaceutical composition for treating periodontal diseases which comprises one or more of therapeutically active ingredients admixed with a polymer capable of dissolving in an aqueous medium of pH 4.0 or higher.

Abstract: A method for treating or preventing periodontal disease which comprises administering ofloxacin or salts thereof locally to periodontal tissue are disclosed. The method is excellent on the treatment of periodontal disease in small dose without disturbance of bacterial flora.

Abstract: A pharmaceutical composition for treating periodontal diseases which comprises one or more of therapeutically active ingredients dispersed in a carrier, characterized in that said carrier consists of(A) water soluble polymer, and(B) polymeric particles having a limited solubility in water,said particles being dispersed in said water soluble polymer.

Abstract: A pharmaceutical composition useful for treatment of periodontal diseases which comprises one or more active ingredients effective for the treatment of periodontal diseases, characterized in that said active ingredient or ingredients are dispersed in collagen.

Abstract: A pharmaceutical composition for the prevention of dental caries which comprises as essential component(s) one or more of pentacyclic acid triterpenes of the formula: ##STR1## wherein R.sub.1 represents CH.sub.3, CHO or CH.sub.2 OH, R.sub.2 and R.sub.3 independently represent CH.sub.3 or COOH, R.sub.4 represents H, CH.sub.3, COOH or COOCH.sub.3, R.sub.5 and R.sub.6 independently represent H, CH.sub.3 or OH, and A represents two Hs or O, and their salts.

Abstract: A method of enhancing a fungus-lytic activity of .beta.-1,3-D-glucanase which comprises using said glucanase in the presence of one or more of the activators selected from the group consisting of sodium lauroylsarcosinate, polyoxyethylene alkylphenyl ether, polyoxyethylene alkyl ether, polyoxyethylene polyoxypropylenealkyl ether, benzalkonium chloride, ammonium chloride, chlorhexidine glucuronate, methylparaben, propylparaben, trypsin, Pronase.RTM. and Alcalase.RTM..A method of enhancing a fungus-lytic activity of .beta.-1,3-D-glucanase which comprises using two .beta.-1,3-D-glucanases of different origins is also provided.

Abstract: A cleaning composition for an artificial denture which comprises .beta.-1,3-glucanase as an essential component together with one or more of suitable carriers.

Abstract: A non-fluidizable composition readily convertible into a fluidizable composition by slight stress or pressure, which can be prepared by cooling an emulsion comprisinng a water-immiscible fatty acid, water and an emulsifier from a temperature sufficient to keep the emulsion at a fluidizable state while stirring, stopping the stirring at a temperature not lower than the temperature 5.degree. C. below the congealing temperature of the emulsion and further continuing the cooling to room temmperature and is useful as a base for shaving creams, hair creams, adhesive pastes, printers' inks, shoe polishes, etc.